ArticleCureus2026
Pilomatrix-Like High-Grade Endometrial Carcinoma (PiMHEC) With Secondary Vaginal Involvement: A Rare Variant of CTNNB1-Mutated Endometrial Carcinoma Mimicking Mesonephric-Like Adenocarcinoma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pilomatrix-like high-grade endometrial carcinoma (PiMHEC) is a recently recognized, clinically aggressive variant of endometrial carcinoma that is frequently misdiagnosed due to its morphological and immunophenotypic overlap with other high-grade endometrial malignancies. We report a 52-year-old woman who presented with widely metastatic high-grade carcinoma of endometrial origin, involving the vagina and distant sites including the brain, lung, and lymph nodes. Histologically, the tumor displayed a predominantly solid basaloid architecture with extensive geographic necrosis and abrupt keratinization with conspicuous shadow cells, supporting pilomatrix-like differentiation. Immunohistochemically, the tumor demonstrated strong, diffuse, aberrant nuclear β-catenin expression; patchy, heterogeneous expression of TTF1, GATA3 and CD10; and variable expression of CK7, CDX2, and p16. The tumor was negative for PAX8, ER, PR, and p40. p53 showed a wild-type pattern, and mismatch repair was retained (pMMR). Next-generation sequencing (NGS) identified a pathogenic exon 3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.